Redwood Wealth Management Group LLC Raises Position in Pfizer Inc. (NYSE:PFE)

Redwood Wealth Management Group LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,865 shares of the biopharmaceutical company’s stock after acquiring an additional 1,405 shares during the quarter. Redwood Wealth Management Group LLC’s holdings in Pfizer were worth $696,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Gilbert & Cook Inc. raised its holdings in Pfizer by 3.8% in the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 945 shares in the last quarter. Gryphon Financial Partners LLC raised its holdings in shares of Pfizer by 43.7% in the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 8,194 shares in the last quarter. Fiera Capital Corp purchased a new stake in shares of Pfizer during the 4th quarter worth $718,000. Financial Advocates Investment Management grew its stake in shares of Pfizer by 3.2% during the fourth quarter. Financial Advocates Investment Management now owns 43,856 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 1,359 shares in the last quarter. Finally, Balentine LLC increased its holdings in Pfizer by 23.7% in the fourth quarter. Balentine LLC now owns 92,725 shares of the biopharmaceutical company’s stock valued at $2,670,000 after buying an additional 17,755 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.4 %

Shares of NYSE PFE opened at $29.27 on Monday. The firm’s 50-day moving average is $29.21 and its two-hundred day moving average is $28.13. The company has a market capitalization of $165.86 billion, a PE ratio of -487.83, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.42. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.74%. Pfizer’s payout ratio is currently -2,800.00%.

Analyst Ratings Changes

A number of analysts have issued reports on PFE shares. UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, September 9th. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.